SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51778The FDA may have reacted to pressure from Alzheimer's groups, which would giArt Bechhoefer16/10/2021
51777Well, then, that's interesting in that they had all those programs last weekLance Bredvold-6/10/2021
51776PRTA jumped on Aduhelm’s approval because PRTA has some preclinical AD programs:DewDiligence_on_SI16/10/2021
51775PRTA; Having gained significant profits from Elan, I continue to hold Prothena Lance Bredvold-6/10/2021
51774Of course - aligning interests of management and shareholders is a pretty good tnigel bates-6/8/2021
51773Derek Lowe - "one of the worst FDA decisions I've seen"... blogs.snigel bates-6/8/2021
51772Because Aduhelm does not cure the disease but merely slows its progression by atArt Bechhoefer-6/8/2021
51771The FDA has a fairly long history of approving new drugs that had some issues wiArt Bechhoefer-6/8/2021
51770"...it appears that many biotech firms are relying on sudden increases in tnigel bates-6/8/2021
51769And the charge is considerable - $56K/year! Push-back from payers? One insurerA.J. Mullen-6/7/2021
51768Ps. The results of the post-marketing trial should give a clear and unequivocalA.J. Mullen-6/7/2021
51767Fueurstein's take on the approval, statnews.com The drug clears out amyloidA.J. Mullen26/7/2021
51766Biogn's aducanimub Alzheimer's drug was approved by the FDA this morningArt Bechhoefer16/7/2021
51765The Biogen drug, it seems to me, if approved will be limited to certain kinds ofArt Bechhoefer-6/7/2021
51764CYCN has a market cap a bit over $100m - in view of the out licensing deal they nigel bates-6/7/2021
51763Anavex, Cyclo Therapeutics, And Green Valley: Stalling Alzheimer's Disease PThehammer-6/4/2021
51762The recent share buying by Hecht appears significant. But there are other firmsArt Bechhoefer-6/4/2021
51761Just out-licensed a non core asset for decent chunk of bio bucks, and a bit of rnigel bates-6/4/2021
51760AI and Synthetic Biology Are Critical to Future U.S. Competitiveness warontheroFrank Sully-5/30/2021
51759The AI that was discussed was applied in pre-clinical studies - long before any A.J. Mullen-5/23/2021
51758Isn’t the AI mantra just an extension of the [noun]-omics approach? It still retechnetium-5/23/2021
51757IndyGeneUS AI secures pathogen sequencing capability to support COVID-19 genomicFrank Sully-5/19/2021
51756Reading through the document you cited, it appears that the agency will review tArt Bechhoefer-5/19/2021
51755What does this mean for Roxadustat Europe? ema.europa.eu 17 May 2021 EMA/CHMP/Joe Wesley-5/19/2021
51754 Moderna leveraging its 'AI factory' to revolutionise the way diFrank Sully15/18/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News